Abstract
The inhibitory capacity of uremic serum over some in vitro immunological events is well known.(1–5) This effect has been ascribed to the uremic toxins that are retained and not eliminated by extrarenal methods. Middle molecules (MM) could be included in these kinds of factors.(6) The depuration capacity of hemodialysis for the serum inhibitory factors has been tested in some studies with contradictory results.(1,2,7) Here we compare the acute effect of hemodialysis with three different membranes versus peritoneal dialysis in their ability to eliminate the uremic inhibitory substances.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Touraine JL, Touraine F, Revillard JP, Brochier J, Traeger J. Nephron 1975; 14: 195–208.
Mezzano S, Pesce AJ, Pollak VE, Michael JG. Nephron 1984; 36: 15–19.
Raska K, Morrison AB, Raskova J. Lab Invest 1980; 42: 636–642.
Raskova J, Raska K. Lab Invest 1981; 45: 410–417.
Holdsworth SR, Fitzgerald MG, Hosking CS, Atkins RC. Clin Exp Immunol 1978; 33: 95–101.
Navarro J, Grossetete MC, Defrasne A, Touraine JL, Traeger J. Nephron 1985; 40: 396–400.
Kamata K, Okubo M, Sada M. Clin Exp Immunol 1983; 54: 277–281.
Boyum A. Scand J Clin Lab Invest 1968; 97 (5): 77.
Atkins RC, Holdsworth SR, Fitzgerald MG, Hosking CS. Clin Exp Immunol 1978; 33: 102–106.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Plenum Publishing Corporation
About this chapter
Cite this chapter
Gonzalez, M. et al. (1990). Effect of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis on the Transport of Inhibitory Factors of Lymphocyte Proliferation Present in Uremic Serum. In: Avram, M.M., et al. Ambulatory Peritoneal Dialysis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9555-7_22
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9555-7_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-9557-1
Online ISBN: 978-1-4615-9555-7
eBook Packages: Springer Book Archive